PhosPrint is a laser bioprinter developer focusing on the highly precise and rapid delivery of cells and other bio-inks on the substrates of interest for tissue regeneration and biosensor applications.
Meet PhosDB I
A high-resolution, user-friendly laser bioprinter
for demanding cell-printing applications
.
Networking & Ecosystems
Contact
Phos Print
Lefkippos Technology Park, NCSR Demokritos
Patriarchou Grigoriou 5’ & Neapoleos 27
153 41, Agia Paraskevh, Athens, Greece
Tax Registration Number: 801099345
General Electronic Commercial Registry (GEMI)
Nr: 149072501000
Latest news
events | press releases | media coverage
14 March 2023
Dedication for the spin-off companies of NTUA and EPISEY
Read here the article dedicated to the spin-off companies that have been founded at NTUA and EPISEY, including PhosPrint, as hosted in the print edition of Kathimerini and on kathimerini.gr. We sincerely thank the journalist Tassoula Karaiskakis. PhosPrint is on the news!
1 February 2023
We are extremely proud and delighted to announce that we won the 3rd place in the 2023 Startup Challenge event that took place on January 31st, during the SPIE Photonics West event in San Francisco. Our CEO, Ioanna Zergioti, presented our pitch during the challenge and Clinical Director, Apostolos Klinakis, represented us at the event.
13 January, 2023
LIBRA (LIGHT BASED MULTISENSING DEVICE FOR SCREENING OF PATHOGENS AND NUTRIENTS IN BIOREACTORS) was officially kicked-off via a meeting that took place in Athens, Greece on January 13th, 2023.
30 October, 2022
Following up on our announcement of 14 October 2022 for being one of the 75 SMEs- and the only one in Greece- selected for Funding in the most recent applications from EIC Accelerator, we were honored to be featured in the financial pages of Sunday edition of Kathimerini newspaper on the 30th of October, p.13. Our CEO Ioanna Zergioti was interviewed by Dimitris Delevegos for the innovative method for regenerative medicine that has been developed by PhosPrint.
The technology reached the current stage after 6 years of persistent research and the 3D laser printer that was developed, allows the successful printing of 100M cells in just 1.6 minutes, targeting enterocystoplasty and bladder cancer. The printing of cells takes place during in vivo surgery and has been effectively tested in pigs. Full adaptation of this method from medical facilities and hospitals after the preclinical trials, prerequires the successful completion of three stages of clinical trials. PhosPrint’s funding from eicAccelerator will be used towards the first clinical trial phase and to this end, the company is now having preliminary discussions with surgeon urologists across the country.
The registration of the intellectual property was supported by the "Grant Program for the Registration of Patent Rights", the result of a partnership between the Bodosakis Foundation, the A. G. Leventis Foundation, the Ioannis S. Latsis Foundation, and the Onassis Foundation
14 October, 2022
We are delighted, honored and extremely proud to be one of the 75 #SMEs to be selected for Funding in the most recent applications from #eicAccelerator. Our journey is just beginning! Many thanks to those who contributed to the achievement of this very significant milestone in the development of #Phosprint.
Με μεγάλη χαρά, τιμή και περηφάνια σας ανακοινώνουμε ότι η Phosprint IKE ειναι μία από τις 75 #SMEs που επιλέχθηκαν για χρηματοδότηση στον πρόσφατο κύκλο αιτήσεων του #eicAccelerator. Το ταξίδι μας μόλις ξεκίνησε, και θέλουμε να ευχαριστήσουμε όσες και όσους συνεισέφεραν για να κατακτήσουμε αυτό το σημαντικό ορόσημο.
Η κατοχύρωση της διανοητικής ιδιοκτησίας υποστηρίχθηκε από το «Πρόγραμμα Επιχορήγησης Δαπανών Κατοχύρωσης Δικαιωμάτων Ευρεσιτεχνίας», αποτέλεσμα σύμπραξης του Ιδρύματος Μποδοσάκη, του Ιδρύματος Α. Γ. Λεβέντη, του Κοινωφελούς Ιδρύματος Ιωάννη Σ. Λάτση, και του Ιδρύματος Ωνάση.
The registration of the intellectual property was supported by the "Grant Program for the Registration of Patent Rights", the result of a partnership between the Bodosakis Foundation, the A. G. Leventis Foundation, the Ioannis S. Latsis Foundation, and the Onassis Foundation.
12-13 May, 2022
The Tumor-LN-oC consortium in Eindhoven for the 12-month meeting of the project. After one year of Tumor-LN-oC, we see significant progress in the development of the microfluidic platform and partners used this chance to discuss challenges and next steps
14.04.22
6-Month UroPrint Project Meeting!
26.03.22
Symeon Papazoglou is presenting the article “Laser bioprinting of cell-laden bioinks for organ-on-chip and sensor applications” at SPIE Photonics Europe in Strasbourg.
Visit the SPIE website for more information about the presentation: https://spie.org/photonics-europe/presentation/Laser-bioprinting-of-cell-laden-bioinks-for-organ-on-chip/12135-10?enableBackToBrowse=true
Come meet us in Strasbourg on 4 April 2022 at 16:40!
24.09.21
We are very proud to announce the launch of the EU funded project "UroPrint" (Urinary bladder bioprinting for fully autologous transplantation).
02.09.21
Tumor-LN-oC project 1st press release
For more information please visit the project's website:
07.05.21
We are very proud to announce the launch of the EU funded project "Tumor-LN-oC" (Tumor and Lymph Node on Chip for cancer studies).
01.03.2021
We are proud to announce the start of our collaboration with the Patras Science Park under the Proof of Concept Award.
11.11.20
Ioanna Zergioti, Co-Founder and CTO presents Phosprint during the
webinar "Women in the Greek Entrepreneurial Ecosystem" on 11/11/2020
organized by the global initiative Weekly Women Entrepreneurship 2020.
28.10.20
PhosPrint is proud to announce its participation in the EU funded project “UroPrint” under the H2020-FETOPEN-2018-2020 call
19.08.20
PhosPrint is proud to announce its participation in the EU funded project “Tumor-LN-oC” under the H2020 NMBP-23-2020 call
24.02.20
Our co-founder and CTO Ioanna Zergioti was awarded with the 3D printing award at SPIE Photonics West 2020, 3 February in San Francisco as a recognition for the fundamental work in the development of a single step laser bioprinting and immobilization process that offers a significant step towards research of cell properties confined in scaffold environments.
09.01.20
PhosPrint qualifies for the semi-finals of the SPIE Startup Challenge 2020 at the SPIE Photonics West Conference!
09.12.19
PhosPrint awarded with the Proof of Concept (PoC) Award from Patras Science Park.
28.03.19
PhosPrint receives the Seal of Excellence from the European Commission, for its high-quality project proposal, in a highly competitive evaluation process, submitted under the Horizon 2020 SME Instrument Phase 1 call H2020-EIC-SMEInst-2018-2020 (H2020-SMEInst-2018-2020-1)